SIRT3 was recently shown to function as a critical source of non-oncogene addiction in DLBCL, due primarily to its role in driving efficient glutamine entry into the tricarboxylic acid (TCA) cycle (9). Here, SIRT3 is linked to diffuse large B-cell lymphoma.